feature(s) that are proposed for utilization in the hydropower development under consideration, and any other applicable water-related contracts.

7. Identify the organizational structure planned for the long-term operation and maintenance of any proposed hydropower development.

8. Provide a management plan to accomplish such activities as planning, NEPA compliance, lease of power privilege development, design, construction, facility testing, and start of hydropower production. Prepare schedules of these activities as applicable. Describe what studies are necessary to accomplish the hydroelectric power development and how the studies would be implemented.

9. Estimate development cost. This cost should include all investment costs such as the cost of studies to determine feasibility, NEPA compliance, design, construction, associated bonding and financing as well as the amortized annual cost of the investment; also, the annual operation, maintenance, and replacement expense for the hydropower development; lease payments to the United States; and expenses that may be associated with the Fry-Ark Project. If there are additional transmission or wheeling expenses associated with the development of the hydropower development, these should be included. Identify proposed methods of financing and hydropower development. An economic analysis should be presented that compares the present worth of all benefits and costs of the hydropower development.

Selection of Lessee: Reclamation will evaluate proposals received in response to this published notice.

Reclamation will give more favorable consideration to proposals that (1) Are well-adapted to developing, conserving, and utilizing the water and natural resources, (2) clearly demonstrate that the offeror is qualified to develop the hydropower facility and provide for long-term operation and maintenance, and (3) develop the hydropower potential economically. Credit will be given to those proposals that demonstrate development of power in an environmentally-friendly manner. While all developments will be required to perform NEPA analysis, proposals should include information as to how the proposer will minimize environmental impact during construction, maintenance and operation. Proposers should also include design characteristics and methods that will be used to minimize environmental impacts and improve the

environmental attributes of the facility. Any work the developer is proposing to do to enhance the ecosystem should also be explained in the proposal. A proposal will be deemed unacceptable if it is inconsistent with Fry-Ark Project purposes, as determined by Reclamation. Reclamation will give preference to those entities that qualify as preference entities (as defined under Proposal Content Guidelines, item 1.) provided that their proposal is at least as well-adapted to developing, conserving, and utilizing the water and natural resources as other submitted proposals and that the preference entity is well qualified. Preference entities would be allowed 90 days to improve their proposals, if necessary, to be made at least equal to a proposal that may have been submitted by a nonpreference entity.

Power Purchasing and/or Marketing Considerations: Western would have the first opportunity to purchase and/or market the power that would be generated by the project under a lease of power privilege. Western will consult with Reclamation on such power purchasing and/or marketing considerations.

In the event Western elects to not purchase and/or market the power generated by the hydropower development or such a decision cannot be made prior to execution of the lease of power privilege, the lessee would be responsible for marketing the power generated by the project with priority given to preference entities as heretofore defined in Proposal Content Guidelines, item 1.

Notice and Time Period to Enter Into Lease of Power Privilege: Reclamation will notify, in writing, all entities submitting proposals of Reclamation's decision regarding selection of the potential lessee. The selected potential lessee will have 2 years from the date of such notification to enter into a lease of power privilege for the site or sites identified in the proposal. This period may only be extended by the United States in writing. Such leases of power privilege will state whether and how Western will be involved in purchasing and/or marketing the power.

Dated: April 14, 2011.

#### Michael J. Ryan,

Regional Director.

[FR Doc. 2011–9533 Filed 4–19–11; 8:45 am]

BILLING CODE 4310-MN-P

# INTERNATIONAL TRADE COMMISSION

Inv. No. 337-TA-756

In the Matter of Certain Reduced Ignition Proclivity Cigarette Paper Wrappers and Products Containing Same; Notice of Commission Determination Not To Review an Initial Determination Granting Complainant's Motion To Amend the Complaint and Notice of the Investigation

**AGENCY:** U.S. International Trade Commission.

**ACTION:** Notice.

**SUMMARY:** Notice is hereby given that the U.S. International Trade Commission has determined not to review an initial determination ("ID") (Order No. 5) of the presiding administrative law judge ("ALJ") granting complainant's motion to amend the complaint and notice of the investigation to add seven respondents to the investigation.

# FOR FURTHER INFORMATION CONTACT:

Michael Haldenstein, Office of the General Counsel, U.S. International Trade Commission, 500 E Street, SW., Washington, DC 20436, telephone 202-205-3041. Copies of the ID and all other nonconfidential documents filed in connection with this investigation are or will be available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street, SW., Washington, DC 20436, telephone 202-205-2000. Hearingimpaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on 202-205–1810. General information concerning the Commission may also be obtained by accessing its Internet server (http://www.usitc.gov). The public record for this investigation may be viewed on the Commission's electronic docket (EDIS) at http://edis.usitc.gov.

#### SUPPLEMENTARY INFORMATION: On

January 13, 2011, the Commission instituted an investigation under section 337 of the Tariff Act of 1930, 19 U.S.C. 1337, based on a complaint filed by Schweitzer-Mauduit International, Inc., of Alpharetta, Georgia ("Schweitzer"), alleging a violation of section 337 in the importation, sale for importation, and sale within the United States after importation of certain reduced ignition proclivity cigarette paper wrappers and products containing same by reason of infringement of certain claims of U.S. Patent No. 6,725,867 and U.S. Patent No. 5,878,753. Complainant Schweitzer

named as respondents Astra Tobacco Corporation of Chapel Hill, North Carolina; delfortgroup AG of Traun, Austria; LIPtec GmbH and Julius Glatz GmbH of Neidenfels, Germany.

On March 22, 2011, the ALJ issued an ID (Order No. 5) granting complainant Schweitzer's motion to amend the complaint and notice of the investigation to add seven additional respondents to the investigation. The new respondents are Dosal Tobacco Corp.; Farmer's Tobacco Co.; S&M Brands, Inc.; Tantus Tobacco, LLC; KneX Worldwide, LLC; Dr. Franz Feurstein GmbH; and PapierfabrikWattens GmbH & Co. KG. No party petitioned for review of the subject ID. The Commission has determined not to review the ID.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in section 210.42(h) of the Commission's Rules of Practice and Procedure (19 CFR 210.42(h)).

By order of the Commission. Issued: April 15, 2011.

#### James R. Holbein,

 $Acting \ Secretary \ to \ the \ Commission.$  [FR Doc. 2011–9584 Filed 4–19–11; 8:45 am]

BILLING CODE 7020-02-P

# INTERNATIONAL TRADE COMMISSION

[USITC SE-11-010]

# Government in the Sunshine Act Meeting Notice

AGENCY HOLDING THE MEETING: United States International Trade Commission. TIME AND DATE: April 28, 2011 at 11 a.m. PLACE: Room 110, 500 E Street SW., Washington, DC 20436, Telephone: (202) 205–2000.

**STATUS:** Open to the public. **MATTERS TO BE CONSIDERED:** 

- 1. Agendas for future meetings: none.
- 2. Minutes.
- 3. Ratification List.
- 4. Vote in Inv. Nos. 701–TA–475 and 731–TA–1177 (Final) (Aluminum Extrusions from China). The Commission is currently scheduled to transmit its determinations and Commissioners' opinions to the Secretary of Commerce on or before May 13. 2011.
- 5. Outstanding action jackets: none. In accordance with Commission policy, subject matter listed above, not disposed of at the scheduled meeting, may be carried over to the agenda of the following meeting. Earlier Notification of this meeting was not possible.

By order of the Commission: Issued: April 18, 2011.

#### William R. Bishop,

Hearings and Meetings Coordinator. [FR Doc. 2011–9726 Filed 4–18–11; 4:15 pm] BILLING CODE 7020–02–P

#### **DEPARTMENT OF JUSTICE**

#### **Drug Enforcement Administration**

# Manufacturer of Controlled Substances Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on February 24, 2011, Stepan Company, Natural Products Dept., 100 W. Hunter Avenue, Maywood, New Jersey 07607, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Cocaine (9041)	II
Ecgonine (9180)	II

The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than June 20, 2011.

Dated: April 13, 2011.

## Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2011–9619 Filed 4–19–11; 8:45 am] **BILLING CODE 4410–09–P** 

## DEPARTMENT OF JUSTICE

# **Drug Enforcement Administration**

# Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on November 3, 2010, Noramco Inc., 500 Swedes Landing Road, Wilmington, Delaware 19801– 4485, made application by letter to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Amphetamine (1100)	II
Phenylacetone (8501)	II

The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, **Federal Register** Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than June 20, 2011.

Dated: April 13, 2011.

#### Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2011–9610 Filed 4–19–11; 8:45 am]
BILLING CODE 4410–09–P

## **DEPARTMENT OF JUSTICE**

#### **Drug Enforcement Administration**

# Manufacturer of Controlled Substances; Notice of Registration

By Notice dated June 17, 2010, and published in the **Federal Register** on June 28, 2010, 75 FR 36679, Lin Zhi International Inc., 670 Almanor Avenue, Sunnyvale, California 94085, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:

Drug	Schedule
Tetrahydrocannabinols (7370) 3.4-	 
Methylenedioxymethamphetam- ine (MDMA) (7405).	•
Cocaine (9041)	II
Oxycodone (9143) Hydrocodone (9193)	
Methadone (9250)	II
Dextropropoxyphene, bulk (non-	II
dosage forms) (9273). Morphine (9300)	II

The company plans to manufacture the listed controlled substances as bulk reagents for use in drug abuse testing.